.jpg "HCPH-Riverside-0708-1870×125-Spa (1)")
The Food and Drug Administration approved a new daraxonrasib pancreatic cancer treatment on Wednesday, Aug. 26. The targeted medicine significantly extended survival among adults with previously treated metastatic pancreatic adenocarcinoma.
Daraxonrasib will be sold under the brand name Rasonque. The drug is not a cure, and its approval does not cover every pancreatic cancer patient.
Who Can Receive Daraxonrasib?
The FDA approved daraxonrasib for adults whose pancreatic adenocarcinoma has spread to other parts of the body.
Eligible patients must have received at least one previous systemic treatment. The approval also covers patients who cannot receive multiagent systemic therapy.
Daraxonrasib comes as a tablet. The FDA recommends a 300-milligram dose taken once daily. Treatment can continue until the cancer progresses or side effects become unacceptable.
The drug targets several forms of RAS, a family of proteins involved in tumor growth. Abnormal RAS activity drives cancer development in many pancreatic adenocarcinomas.
Daraxonrasib Pancreatic Cancer Trial Shows Survival Benefit
The approval followed results from RASolute 302, a randomized phase 3 clinical trial. Researchers enrolled 500 adults with previously treated metastatic pancreatic adenocarcinoma.
Half received daraxonrasib. The remaining participants received a standard chemotherapy regimen selected by their doctors.
Patients taking daraxonrasib had a median overall survival of 13.2 months. Median survival was 6.7 months among patients receiving standard chemotherapy.
Therefore, the results nearly doubled median survival in the study population. However, median survival figures do not predict how long an individual patient will live.
Median progression-free survival also improved from 3.6 months with chemotherapy to 7.2 months with daraxonrasib. This measurement reflects how long patients lived without their cancer worsening.
The overall response rate was 30% in the daraxonrasib group. It was 11% among patients receiving standard treatment.
Researchers reported the findings in The New England Journal of Medicine. The trial found statistically significant improvements in survival, disease control and tumor response.
Why the Approval Is Significant
Pancreatic cancer remains one of the most difficult cancers to treat. Doctors often diagnose it after the disease has already spread.
Pancreatic adenocarcinoma begins in cells lining the pancreatic ducts. It represents about 90% to 95% of pancreatic cancer cases, according to the FDA.
The United States records approximately 67,000 new pancreatic cancer cases each year. Although the disease represents a small share of cancer diagnoses, it causes a disproportionate number of deaths.
Treatment options for metastatic disease have historically relied heavily on combinations of chemotherapy drugs. Daraxonrasib introduces a new targeted approach for patients whose disease progressed after earlier treatment.
The FDA granted the medicine Breakthrough Therapy, Orphan Drug and Priority Review designations. Regulators approved it about six and a half months before the agency’s original review deadline.
Risks and Side Effects
The most common side effects include rash, diarrhea, nausea, fatigue and vomiting. Patients may also experience mouth inflammation, abdominal pain, swelling, appetite loss or bleeding.
The prescribing information includes warnings for severe skin and soft tissue reactions. Other warnings cover gastrointestinal perforation, lung inflammation and harm to an unborn child.
Patients should discuss potential benefits, risks and drug interactions with a qualified oncology team. Medical professionals can determine whether the diagnosis and treatment history meet the FDA-approved criteria.
The approval offers meaningful progress, but pancreatic cancer care still requires individualized medical guidance. Patients and families can consult their cancer specialists and review current FDA information before making treatment decisions.